GHB (gamma-hydroxybutyrate) is a central nervous system depressant that acts on GABA and GHB receptors in the brain. Regular use causes physical dependence within days to weeks. When someone stops or sharply reduces their use, withdrawal begins rapidly and can become life-threatening.
Medical detox is the safest and most effective way to manage GHB withdrawal and reduce the risk of serious complications such as seizures and delirium [1].
GHB was mainly misused in the 1980s in the bodybuilding community and in the 1990s as a recreational drug at electronic dance music venues, where it was renamed the “date rape drug”. While not as commonly used as other drugs, there is some increase among young adults.
Due to the severity and complexity of withdrawal, it places a high burden on resources in hospital emergency departments.
GHB works by suppressing excitatory activity in the brain. With repeated use, the brain adjusts by becoming more excitable on its own. When GHB is removed, that excess excitability goes unchecked. The result is a rapid surge in stimulation across the nervous system that can produce severe and unpredictable symptoms [2].
GHB withdrawal resembles alcohol and benzodiazepine withdrawal but tends to progress faster and carry a higher risk of psychosis and delirium. One study found that delirium occurred in up to 12% of people who were going through GHB withdrawal, while it only happened in about 5% of people who were going through alcohol withdrawal [3].
Because tolerance can build in just days, even people who have used GHB for a short time may experience severe withdrawal.
A review of 27 studies identified the most frequent withdrawal symptoms across a large number of reported cases [3]. These included:
In some severe cases, people also develop hyperthermia (dangerously high body temperature) and rhabdomyolysis, a breakdown of muscle tissue that can damage the kidneys [2]. These complications may require intensive care.
GHB leaves the body quickly, so withdrawal begins faster than with alcohol or opioids. The timeline below reflects typical patterns in clinical settings, though individual experience can vary based on dose frequency and duration of use.
| Phase | Timing | What Happens |
| Early onset | 1–6 hours | Anxiety, insomnia, tremors, sweating, cramps |
| Peak intensity | 6–72 hours | Hallucinations, delirium, seizures, autonomic instability |
| Subacute phase | Days 3–14 | Cravings, fatigue, mood changes, lingering insomnia |
People who use GHB many times a day, every few hours, are at the highest risk of delirium and seizures. A study of 285 patients found that the most common ongoing symptoms after the peak phase included cravings, fatigue, sweating, and sleep problems [4].
GHB withdrawal requires medical supervision. Attempting to stop without clinical support carries serious risk. There is currently no universally agreed-upon protocol, but several approaches have strong evidence [5].
Benzodiazepines such as diazepam are the most widely used first-line medication. They calm excitatory activity in the brain and help prevent seizures. However, because GHB acts on GABA-B receptors and benzodiazepines act mainly on GABA-A receptors, some patients do not respond well to benzodiazepines alone [6].
For these patients, additional treatments may be used. Baclofen, a GABA-B receptor agonist, has shown promise in cases where benzodiazepines are not enough.
In the Netherlands, healthcare providers widely use pharmaceutical GHB tapering, which involves slowly weaning patients off with medical-grade doses. In one study of 229 patients using this approach, 85% completed detox in about 12.5 days [7]. Other options include phenobarbital, propofol, and dexmedetomidine for severe or refractory cases.
While completing detox is a critical first step, it does not end the recovery process. Relapse rates after GHB detox are high. Most patients relapsed within three months of completing detox in one Dutch study. Sleep disturbances and cravings frequently persisted well after the acute phase ended. Relapse risk is known to increase with these ongoing symptoms [4].
The best chance at lasting recovery after detox is through ongoing care that addresses both the physical and psychological dimensions of dependence.
Therapeutic approaches such as cognitive behavioral therapy, motivational interviewing, and peer support programs are beneficial. An important part of the recovery process involves treating any co-occurring mental health conditions, such as anxiety or depression.
For those seeking this level of specialized, integrated care in the San Francisco Bay area, Alta Mira Recovery Programs is a high-end, top-tier residential addiction center specializing in the treatment of substance use disorders and complex co-occurring mental health issues.
Our exceptional team of highly credentialed addiction treatment professionals provides the most sophisticated level of clinical care and diagnostic services, reflecting our appreciation for your unique qualities.
Contact our compassionate admissions team to learn more.
| [1] | Persic, V., et al. (2020). Gamma-hydroxybutyrate abuse: Pharmacology and poisoning and withdrawal management. Acta Clinica Croatica, 59(4), 784–791. Gamma-Hydroxybutyrate Abuse: Pharmacology and Poisoning and Withdrawal Management |
| [2] | Weenink, R., et al. (2021). Successful treatment of severe gamma-hydroxybutyric acid withdrawal syndrome with dantrolene. Frontiers in Psychiatry, 12, 665442. Successful Treatment of Severe Gamma-Hydroxybutyric Acid Withdrawal Syndrome With Dantrolene |
| [3] | Yeh, Y. W., et al. (2018). Clinical management of gamma-hydroxybutyrate (GHB) withdrawal delirium with CIWA-Ar protocol. Asian Journal of Psychiatry, 36, 98–101. Clinical Management of Gamma-Hydroxybutyrate (GHB) Withdrawal Delirium with CIWA-Ar Protocol |
| [4] | Beurmanjer, H., et al. F. A. (2021). Characterization of the GHB withdrawal syndrome. International Journal of Environmental Research and Public Health, 18(12), 6403. Characterization of the GHB Withdrawal Syndrome |
| [5] | Beurmanjer, H., et al. (2024). Pharmacological treatment of GHB withdrawal syndrome. Current Addiction Reports, 11, 250–258. Pharmacological Treatment of GHB Withdrawal Syndrome |
| [6] | LeTourneau, J., et al. (2008). Baclofen and gamma-hydroxybutyrate withdrawal. Neurocritical Care, 8(3), 430–433. Baclofen and Gamma-Hydroxybutyrate Withdrawal |
| [7] | Phan, V., et al. (2022). Current insights on the impact of gamma-hydroxybutyrate (GHB) abuse. Frontiers in Psychiatry, 13, 798296. Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse |
